Midterm results after aortic valve replacement with freehand stentless xenografts: a comparison of three prostheses.

Abstract Objective: The ideal substitute for the diseased aortic valve is yet to be found. For the assessment and comparison of the midterm results after aortic valve replacement with three different types of freehand stentless xenografts, all patients who underwent the operation between October 1992 and April 1997 were reviewed. Methods: Of 231 patients undergoing aortic valve replacement, 106 patients (group 1) were given the Biocor PSB (Biocor Industria e Pesquisa Ltda, Belo Horizonte, MG, Brazil); 76 patients (group 2) were given the Toronto SPV (St. Jude Medical, Inc., St. Paul, Minn.), and 49 patients (group 3) were given the O'Brien-Angell valve (Bravo Cardiovascular model 300, Cryolife, Inc., Marietta, Ga.). The first two xenografts require inflow and outflow suturelines; the third xenograft needs a single-sutureline implantation. Mean age (70 ± 6 years; 70 ± 7 years; 72 ± 9 years; p  = 0.6), prevalence of male sex (56 patients, 53%; 37 patients, 49%; 22 patients, 45%; p  = 0.7), of aortic stenosis (72 patients, 68%; 54 patients, 71%; 37 patients, 73%; p  = 0.6), and need for associated procedures (51 patients, 48%; 30 patients, 40%; 21 patients, 43%; p  = 0.1) were comparable among groups. Mean aortic crossclamp time was shorter in group 3 (96 ± 24 minutes; 100  ± 23 minutes; 88 ± 25 minutes; p  = 0.01). Results: Early deaths were 3 of 106 (3%) in group 1, 2 of 76 (3%) in group 2, and 2 of 49 (4%) in group 3. Follow-up of survivors ranged from 1 to 54 months (mean 32 ± 13 months). Survival at 4 years was 90% ± 3% in group 1, 95% ± 3% in group 2, 85% ± 8% in group 3 ( p  = 0.3). At 4 years, freedom from valve-related events was 95% ± 6%, 100%, 70% ± 8% ( p  = 0.004), while freedom from valve deterioration was 99% ± 1%, 100%, 73% ± 8% ( p  = 0.001), in group 1, 2, and 3, respectively ( p  = 0.001). At follow-up, reintervention on the xenograft was necessary in one patient (endocarditis) in group 1, none in group 2, and six in group 3 (technical cause, group 3; valve tear, group 2; pannus, group 1). Regression analysis showed O'Brien-Angell type of xenograft to be predictive of valve-related events ( p  = 0.02), valve deterioration ( p  = 0.001), and reoperation ( p  = 0.001) during follow-up. Conclusions: Midterm survival after stentless aortic valve replacement is good with all three xenografts. Freedom from valve-related events, valve deterioration, and reoperation are excellent with the Biocor PSB or the Toronto SPV stentless valves but less satisfactory with the O'Brien-Angell valve. (J Thorac Cardiovasc Surg 1998;115:1287-97)